Bavarian Nordic ASBVNKF 82 EBITDA Margin % is 18.64% as of Mar. 2026, which is 10% above its 10-year median of 17.01. GuruFocus rates BVNKF with a GF Score™ of 82/100 and a GF Value™ of $25.88 (Fairly Valued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Bavarian Nordic AS ranks better than 91.64% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bavarian Nordic AS's EBITDA for the
three
months ended in Mar. 2026 was $30.5 Mil. Bavarian Nordic AS's Revenue for the
three
months ended in Mar. 2026 was $163.6 Mil. Therefore, Bavarian Nordic AS's EBITDA margin for the quarter that ended in Mar. 2026 was 18.64%.
Bavarian Nordic AS (OTCPK:BVNKF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bavarian Nordic AS EBITDA Margin % Related Terms
Bavarian Nordic AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BVNKF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS (BVNKF) has a EBITDA Margin % of 18.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bavarian Nordic AS and its competitors. This is 10% above median its historical median of 17.01. According to the industry distribution chart, Bavarian Nordic AS ranks #79 out of 945 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Bavarian Nordic AS's EBITDA Margin % too high?
Bavarian Nordic AS's current EBITDA Margin % of 18.64% is 10% above median its 10-year median of 17.01. Based on the distribution chart, Bavarian Nordic AS ranks #79 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #79 out of 945 companies for EBITDA Margin %. This places Bavarian Nordic AS in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bavarian Nordic AS and its competitors. Bavarian Nordic AS's current EBITDA Margin % is 18.64%, which is 10% above median its own 10-year median of 17.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (BVNKF) is currently considered Fairly Valued. The stock's GF Value™ is $25.88, compared to a current price of $27.80 — trading 7.4% above its estimated fair value. The current EBITDA Margin % is 18.64%, which is 10% above median its 10-year median of 17.01. Bavarian Nordic AS's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bavarian Nordic AS (BVNKF), the current EBITDA Margin % is 18.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (BVNKF) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of $27.80 is trading 7.4% above its estimated GF Value™ of $25.88.
GuruFocus considers Bavarian Nordic AS to be Fairly Valued.
Key valuation signals for BVNKF:
EBITDA Margin %: 18.64% (10% above median its 10-year median of 17.01)
GF Value™: $25.88 vs. price of $27.80 (7.4% above fair value)
No single metric tells the full story. See the BVNKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
82GF Score
Get the complete analysis for BVNKF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVNKF has been successfully added to your 
